ANX-005

Summary

Anx-005 (CHEMBL4650442) is a phase-3 clinical-stage unknown; indicated across 4 conditions including guillain-barre syndrome and autoimmune hemolytic anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650442
Name	ANX-005
Type	Unknown
Max phase	3

Also known as: Anx-005, ANX-005, Anx005, ANX005

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Guillain-Barre syndrome	3	MONDO:0016218	EFO:0007292
autoimmune hemolytic anemia	2	MONDO:0020108	EFO:1001264
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
Huntington disease	2	MONDO:0007739	MONDO:0007739

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04701164	PHASE3	COMPLETED	Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
NCT04514367	PHASE2	COMPLETED	An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington’s Disease
NCT04569435	PHASE2	COMPLETED	Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04691570	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT03010046	PHASE1	TERMINATED	Single Dose Study of ANX005 in Healthy Volunteers
NCT04035135	PHASE1	COMPLETED	A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).